ABSTRACT
INTRODUCTION Acute coronary syndromes (ACS) account for the majority of the morbidity and mortality in patients with coronary artery disease. Despite continued advances, not only in pharmacological and mechanical reperfusion, but also in adjunctive therapies such as -blockers, angiotensin-converting enzyme inhibitors, HMG CoA reductase inhibitors, and enhanced anti-platelet therapy (e.g., glycoprotein IIb/IIIa inhibitors), a substantial adverse event rate persists for patients who present with ACS [1].
